REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)
$6.61 0.35 (5.5911%)
Analysed REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) News Sources
Tango data add to growing momentum for pancreatic cancer drugs
08-06-2026
biopharmadive.com
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?
08-06-2026
yahoo.com
Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents
08-06-2026
yahoo.com
Top Midday Gainers
08-06-2026
yahoo.com
Tango Skyrockets On Eye-Popping Pancreatic Cancer Results
08-06-2026
yahoo.com
Tango Therapeutics stock surges on pancreatic cancer trial data
09-06-2026
qz.com
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
09-06-2026
yahoo.com
Can Revolution Medicines Be a Game-Changer Stock?
11-06-2026
fool.com
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD
12-06-2026
yahoo.com
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy
13-06-2026
yahoo.com
What is the current price of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The current price of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is $6.61.
REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) absolute price change since previous trading day?
The absolute price change of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) since the previous trading day is $0.35.
REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) percentage price change since previous trading day?
The percentage price change of REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) since the previous trading day is 5.5911%.
What is the most recent average sentiment score for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The most recent average sentiment score for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)?
The most recent sentiment for REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ) is .
SEC-8K** Filing Available For REVOLUTION MEDICINES INC-28 (RVMDW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.